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The standard treatment of many tumor entities comprises fractionated radiation therapy
which applies ionizing radiation to the tumor-bearing target volume. Ionizing radiation
causes double-strand breaks in the DNA backbone that result in cell death if the number
of DNA double-strand breaks exceeds the DNA repair capacity of the tumor cell. Ionizing
radiation reportedly does not only act on the DNA in the nucleus but also on the plasma
membrane. In particular, ionizing radiation-induced modifications of ion channels and
transporters have been reported. Importantly, these altered transports seem to contribute
to the survival of the irradiated tumor cells. The present review article summarizes
our current knowledge on the underlying mechanisms and introduces strategies to
radiosensitize tumor cells by targeting plasma membrane ion transports.
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INTRODUCTION
Increasing pieces of evidence strongly indicate that ion trans-
ports across biological membranes fulfill functions beyond those
described by classical physiology such as epithelial transports and
neuronal or muscle excitability. More and more, it turns out that
ion transports are involved in virtually all cell-biological pro-
cesses. By modifying the chemistry, electricity and mechanics
of cells, ion transports directly interact with cellular biochem-
istry and constitute signaling modules that are capable of altering
protein function, gene expression (Tolon et al., 1996) and epige-
netics (Lobikin et al., 2012). Moreover, ion transport-generating
proteins such as ion channels have been identified to directly
signal in macromolecular complexes with, e.g., surface recep-
tors and downstream kinases (Arcangeli, 2011), or to directly
bind to DNA as transcription factors (Gomez-Ospina et al.,
2006).
Over the past two decades, ion transports camemore andmore
in the focus of oncological research. Increasingly, data accumu-
late indicating tumor-suppressing as well as oncogenic functions
of ion transport processes. In particular, ion transports have been
identified as key regulators of neoplastic transformation, malig-
nant progression, tissue invasion and metastasis (for review see
Huber, 2013). Most recent data suggest that ion transports may
also contribute to therapy resistance especially to radioresistance
of tumor cells. The second chapter of this review article aims at
giving an overview of those data. Since worldwide, only a hand-
ful of laboratories including ours are working in this research
field only few data on ion transports in radioresistance are avail-
able and in most cases, the underlying molecular mechanisms
of the observed phenomena remain ill-defined. Because tumor
hypoxia is a major obstacle in radiotherapy, the second chap-
ter also includes ion transports in the mitochondria that confer
hypoxia resistance to normal tissue and probably also to tumor
cells. At the end, this article provides some ideas how the acquired
knowledge might be harnessed in the future for new strategies
of anti-cancer therapy that combine ion transport-targeting and
radiotherapy. To begin with, a brief introduction into radio-
therapy and its radiobiological principles is given in the next
paragraphs.
RADIOTHERAPY
According to the GermanCancer Aid, 490,000 people in Germany
are diagnosed with cancer every year (German-Cancer-Aid,
2013a) (data originating from February 2012), 218,000 die from
their disease. About half of all cancer patients receive radia-
tion treatment, half of all cures from cancer include radio-
therapy (German-Cancer-Aid, 2013b). Radiotherapy is one of
the main pillars of cancer treatment together with surgery and
systemic therapy, mainly chemotherapy. Examples for curative
radiotherapy without surgery are prostate (Eckert et al., 2013;
Kotecha et al., 2013) and head and neck cancer (Glenny et al.,
2010). Preoperative radiotherapy is applied in rectal cancer
(Sauer et al., 2012), postoperative treatment in breast cancer
(Darby et al.). Yet, also rare tumor entities like sarcoma and
small cell carcinoma are treated with radiotherapy (Eckert et al.,
2010a,b; Muller et al., 2012). Despite modern radiation tech-
niques and advanced multimodal treatments local failures and
distant metastases often limit the prognosis, especially due to
limited salvage treatments (Muller et al., 2011; Zhao et al.,
2012).
INTRINSIC AND HYPOXIC RADIORESISTANCE
Radiation therapy impairs the clonogenic survival of tumor cells
mainly by causing double strand breaks in the DNA backbone.
The number of double strand breaks increases linearly with the
absorbed radiation dose (unit Gray, Gy). The intrinsic capacity
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to repair these DNA damages by non-homologous end joining
or homologous recombination determines how radio resistant a
given tumor cell is. Irradiated tumor cells which leave residual
DNA double strand breaks unrepaired lose their clonogenicity
meaning that these cells cannot restore tumor mass. Ion trans-
ports may directly be involved in the cellular stress response to
DNA damage by controlling cell cycle, metabolic adaptations or
DNA repair and, thus, contribute to intrinsic radioresistance and
the survival of the tumor cell.
Besides intrinsic factors, the microenvironment influences
the radiosensitivity of a tumor. Hypoxic areas frequently occur
in solid tumors. Hypoxic tumor cells, however, are somehow
“protected” from radiotherapy [reviewed in Harada (2011)].
This is because ionizing radiation generates directly or indi-
rectly radicals in the deoxyribose moiety of the DNA backbone.
In a hypoxic atmosphere, thiols can react with those DNA
radicals by hydrogen atom donation which results in chemi-
cal DNA repair. In the presence of oxygen, in contrast, oxy-
gen fixes radicals of the deoxyribose moiety to strand break
precursors (Cullis et al., 1987). This so called oxygen effect
radiosensitizes tumor cells by a factor of two to three (oxy-
gen enhancement ratio) as compared to the hypoxic situation
(Langenbacher et al., 2013). Accordingly, patients with hypoxic
tumors who undergo radiotherapy have a worse prognosis than
those with normoxic tumors [e.g., cervical cancer (Fyles et al.,
2002, 2006)]. Notably, ion transport processes have been iden-
tified as important players in the adaptation of tumor cells to
a hypoxic microenvironment. Hence, ion transports via adapta-
tion to hypoxia also indirectly contribute to the radioresistance
of tumors.
In radiotherapy, fractionated treatment regimens have been
established which may reoxygenate and thereby radiosensitize
the irradiated tumor during therapy time. In addition, frac-
tionated radiotherapy spaces out the single fractions in a way
that allows DNA repair of normal tissue, that re-distribute
cell cycle of the tumor cells in more sensitive phases and
that minimize repopulation of the tumor during therapy. The
next paragraphs will give an introduction to the underlying
radiobiology.
FRACTIONATED RADIATION THERAPY. REPAIR, REOXYGENATION,
REDISTRIBUTION, AND REPOPULATION
Early in historic development of radiotherapy fractionation was
introduced as a means to limit side effects when giving therapeu-
tic radiation doses (Bernier et al., 2004). Standard fractionation is
defined as single doses of 1.8–2 Gy, once daily, 5 days per week.
The principal rationale for fractionation is based on the fact
that recovery after radiation is better in normal tissue than in
tumors, especially concerning late reacting tissues responsible
for late side effects of radiotherapy (Jones et al., 2006) such
as fibrosis, damage of spinal cord and brain, as well as most
inner organs. Radiation with high single doses is only possi-
ble without increased side effects if the radiation field can be
confined to the tumor (e.g., stereotactic radiotherapy of brain
metastases [Rodrigues et al., 2013) and SBRT, stereotactic body
radiation therapy (Grills et al., 2012)]. Yet, many situations in
radiation oncology such as adjuvant treatment or irradiation of
nodal regions require irradiation of significant volumes of normal
tissue.
Alpha-beta ratios
Acute effects of ionizing irradiation on clonogenic cell sur-
vival in vitro as well as on late toxicity of the normal tissue
in patients which underwent radiotherapy are described by the
linear-quadraticmodel (Barendsen, 1982; Dale, 1985). The math-
ematical fit of the clonogenic survival (late toxicity) is calculated
as follows: N = N0 × E−(αD−βD∧2) with N being the number of
surviving cells (patients without late toxicity), N0 being the ini-
tial number of cells (number of patients receiving radiotherapy),
α [1/Gy] and β [1/Gy∧2] being cell (tissue)-specific constants and
D the delivered radiation dose. Low alpha-beta ratios (α/β) [Gy]
as determined for many normal tissues indicate that dose frac-
tionation in daily fractions of usually 2 Gy increases survival and
decreases late toxicity as compared to a single equivalent dose.
Tumors with high alpha-beta ratios, in contrast do not bene-
fit from fractionation. For some tumors such as squamous cell
carcinoma of the head and neck there is even a rationale for
hyperfractionated radiotherapy with twice daily irradiation of
1.2–1.4 Gy per fraction [reviewed in Nguyen and Ang (2002)].
The theoretical advantage has been confirmed in clinical tri-
als [e.g., EORTC trial 22791 in advanced head and neck cancer
Horiot et al. (1992)]. Different fractionation schedules for distinct
clinical situations are applied for example in whole-brain radio-
therapy. In prophylactic radiation 2–2.5 Gy fractions are applied
to limit neurocognitive deficits (Auperin et al., 1999; Le Pechoux
et al., 2011; Eckert et al., 2012). For therapeutic radiation 3 Gy
fractions or even 4 Gy fractions are preferred in a palliative set-
ting and limited life expectancy to shorten the treatment time to
5 or 10 days (Lutz, 2007; Rades et al., 2007a,b).
Reoxygenation
As mentioned above, fractionated radiation may also lead to
reoxygenation of the tumor during therapy (Withers, 1975;
Pajonk et al., 2010). Blood vessels of tumors lack normal archi-
tecture and are prone to collapse whenever tissue pressure of
the expanding tumor mass increases. This aggravates tumor mal-
perfusion and accelerates intermittent or chronic tumor hypoxia.
Being sublethal as related to the whole tumor, single radiation
fractions in the range of 2 Gy kill a significant percentage of the
tumor cells which give rise to tumor shrinkage. Shrinkage, in
turn, is thought to increase blood and oxygen supply of the tumor
by improving vessel perfusion and by increasing the ratio of vas-
cularization and the residual tumor mass (Maftei et al., 2011;
Narita et al., 2012). Increased oxygenation then reverses hypoxic
radioresistance of the tumor and improves the therapeutic out-
come of radiotherapy.
Redistribution and repopulation
The sensitivity to radiotherapy during cell cycle differs, being
highest inM and lowest in late S phase of cell cycle (Pawlik and
Keyomarsi, 2004). Often depending on p53 function, irradiated
tumor cells accumulate in G1 or G2 phase of cell cycle to repair
their DNA damages. In a radiation dose-dependent manner, irra-
diated cells are released from cell cycle arrest and re-enter cell
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cycling and tumor repopulation. Importantly, repopulation after
irradiation is often accelerated probably due to selection of more
aggressive tumor cells (Marks and Dewhirst, 1991). Fractionated
radiation regimes aim to re-distribute tumor cells in a more vul-
nerable phase of the cell cycle in the time intervals between two
fractions and to impair repopulation (Pawlik and Keyomarsi,
2004).
CANCER STEM CELLS (CSCs)
Cancer stem cells (CSCs) may resist radiation therapy [for review
see Pajonk et al. (2010)]. Mechanisms that might contribute to
the relative resistance of CSCs as compared to the non-CSC
cells of a given tumor include (i) higher oxidative defense and,
therefore, lower radiation-induced insults, (ii) activated DNA
checkpoints resulting in faster DNA repair, and (iii) an atten-
uated radiation-induced cell cycle redistribution. Fractionation
regimes are designed that way that the macroscopically visible
bulk of tumor cells (i.e., the non CSCs) and not the rare CSCs
become redistributed into a more vulnerable phase of cell cycle
between two consecutive fractions of radiotherapy. Finally, radia-
tion therapy is thought to switch CSCs from an asymmetrical into
a symmetrical mode of cell division; i.e., a CSC which normally
divides into a daughter CSC and a lineage-committed progenitor
cell is induced by the radiotherapy to divide symmetrically into
two proliferative stem daughter cells. This is thought to acceler-
ate repopulation of the tumor after end of radiotherapy (Pajonk
et al., 2010).
In summary, fractionated radiotherapy may radio sensitize
tumor cells by reoxygenation of the tumor and redistribution of
the tumor cells in more vulnerable phases of cell cycle while pro-
tecting at the same time normal tissue if the alpha-beta ratio of
the tumor exceeds that of the normal tissue. On the other hand,
the applied fractionation protocols might spare CSCs due to their
radiobiology that differs from that of the bulk of non-CSCs.
Furthermore, single radiation fractions apply sublethal doses of
ionizing radiation. Data from in vitro and animal studies suggest
that sublethal doses of ionizing radiationmay stimulate migration
and tissue invasion of the tumor cells. Translated into the in vivo
situation, this might imply that cells at the edge of solid tumors
might be stimulated by the first radiation fractions to migrate
out of the target volume of radiation resulting in survival of the
evaded cells and tumor relapse. Moreover, if radiation fractions
further induce tumor cell invasion into blood or lymph vessels,
fractionated radiotherapy regimes might also boost metastases.
As described in the next paragraphs, ion transports fulfill piv-
otal functions in cell migration especially in radiation-induced
migration.
ION TRANSPORTS AND RADIORESISTANCE
Ion transports can be assessed by tracer-flux measurements, flu-
orescence microscopy/photometry using ion species-specific flu-
orescence dyes such as the Ca2+-specific fluorochrome fura-2, as
well as by electrophysiological means. The latter can be applied
if ion transports are electrogenic. Measurements of ion trans-
ports during treatment with ionizing radiation are hardly feasible.
Reported electrophysiological in vitro data on irradiated tumor
cells indicate that radiation-induced transport modifications may
occur instantaneously and may last up to 24 h post irradiation
(Kuo et al., 1993). They further suggest that these modifica-
tions may be induced by doses used for single fractions in the
clinic (Steinle et al., 2011). The following paragraphs summarize
radiation-induced transport modifications as observed in in vitro
studies on tumor cell lines and their putative contribution to
the radioresistance of tumor cells. Whether these processes may
indeed underlie therapy failure in tumor patients can only be
answered if more data from tumor mouse models and clinical
trials become available.
Tumor cells have been proposed to adapt either a “Grow” or
a “Go” phenotype in dependence on changes in their microenvi-
ronment. When developing a certain mass, growing solid tumors
are prone to become malperfused because of the insufficient
tumor vasculature. As a consequence of malperfusion, microen-
vironmental stress by hypoxia, interstitial nutrient depletion, and
low pH increases (Stock and Schwab, 2009; Hatzikirou et al.,
2012) which is thought to trigger at a certain point the induc-
tion of the “Go” phenotype. By migration and tissue invasion
“Go” tumor cells may evade the locally reined stress burden and
resettle in distant and less hostile regions. Once re-settled, tumor
cells may readapt the “Grow” phenotype by reentering cell cycling
and may establish tumor satellites in more or less close vicinity
of the primary focus. Moreover, this stress evasion may lead to
metastases if the “Go” cells invade into blood or lymph vessels.
Migration and tissue invasion are directed by extracellular
hapto- and chemotactic signals which trigger preset “Go” pro-
grams (Schwab et al., 2007, 2012). The latter comprise intracel-
lular signaling, cellular motor functions including cell volume
changes and cytoskeletal dynamics, as well as extracellular matrix
digestion and reorganization. Ion transports have been suggested
to contribute to all of these processes (Schwab et al., 2007, 2012).
As a matter of fact, highly invasive and metastatic phenotypes of
tumor cells often show aberrant activity of certain ion transports.
The following paragraphs describe the role of these ion trans-
ports in particular of those across the plasma membrane using
the example of glioblastoma cells.
MOTOR FUNCTION
Glioblastoma cells exhibit a highly migrative phenotype and
“travel” long distances throughout the brain (Johnson et al.,
2009). Primary foci of glioblastoma show, therefore, even at early
stages of diagnosis a characteristic diffuse and net-like brain
infiltration (Niyazi et al., 2011). Tumor margins are often not
definable and complete surgical tumor resection as well as cap-
ture of all residual tumor cells by the radiation target volume
is hardly possible (Weber et al., 2009). This results in therapy
failure accompanied by very bad prognosis for the survival of
the patient in almost all cases of glioblastoma (Niyazi et al.,
2011). Glioblastoma cells typically migrate into the surround-
ing brain parenchyma primarily by using nerve bundles and the
vasculature as tracks. The close vicinity to the vasculature has
the advantage for the migrating glioblastoma cell of a continu-
ous and sufficient supply of oxygen, nutrients, growth factors,
chemokines, and cytokines (Montana and Sontheimer, 2011).
Glioblastoma cells have to squeeze through very narrow inter-
stitial spaces during their brain invasion along those tracks. This
www.frontiersin.org August 2013 | Volume 4 | Article 212 | 3
Huber et al. Transports and radioresistance
requires highly effective local cell volume decrease and re-increase
procedures. Notably, glioblastoma cells are capable to lose all
unbound cell water leading to maximal cell shrinkage (Watkins
and Sontheimer, 2011). Unusually high cytosolic Cl− concen-
trations (100mM) provide the electrochemical driving force for
this tremendous cell volume decrease. The cytosolic Cl− concen-
tration is built up highly above its electrochemical equilibrium
concentration by the Na/K/2Cl cotransporter NKCC1 (Haas and
Sontheimer, 2010; Haas et al., 2011) allowing glioblastoma cells
to utilize Cl− as an osmolyte.
Local regulatory volume increase and decrease have been pro-
posed to drive migration mechanics. The latter is generated by the
loss of Cl− and K+ ions along their electrochemical gradients fol-
lowed by osmotically obliged water fluxes. Involved transporters
probably are ClC-3 Cl− channels (Olsen et al., 2003; Cuddapah
and Sontheimer, 2010; Lui et al., 2010), Ca2+-activated high con-
ductance BK (Ransom and Sontheimer, 2001; Ransom et al.,
2002; Sontheimer, 2008) as well as intermediate conductance IK
K+ channels (Catacuzzeno et al., 2010; Sciaccaluga et al., 2010;
Ruggieri et al., 2012) and AQP-1 water channels (Mccoy and
Sontheimer, 2007; Mccoy et al., 2010). To a lower extent, K+
and Cl− efflux is probably also mediated by KCC1-generated
cotransport (Ernest et al., 2005). These transports are crucial for
glioblastoma migration since either transport blockade inhibits
glioblastoma cell migration and invasion (Ernest et al., 2005;
Mcferrin and Sontheimer, 2006; Catacuzzeno et al., 2010; Haas
and Sontheimer, 2010; Lui et al., 2010; Sciaccaluga et al., 2010).
Notably, Ca2+-activated BK (Ransom and Sontheimer, 2001;
Liu et al., 2002; Ransom et al., 2002; Weaver et al., 2006) and
IK K+ channels (Ruggieri et al., 2012) are ontogenetically down-
regulated or absent in mature glial cells but up-regulated with
neoplastic transformation and malignant tumor progression as
shown in expression studies in human glioma tissue. Moreover,
glioblastoma cells up-regulate a unique splice variant of the BK
channel (Liu et al., 2002) which exhibits a higher Ca2+ sensitivity
than the other isoforms (Ransom et al., 2002) and is indispensable
for glioblastoma proliferation in vitro. Similarly, ClC-3 Cl− chan-
nels aremal-expressed in glioblastoma tissue where they traffic, in
contrast to normal tissue, to the plasma membrane (Olsen et al.,
2003). The predominant (surface) expression of ClC-3 and the
BK splice variant by glioblastoma cells renders both channel types
putative glioblastoma-specific therapeutic targets.
EVASION FROM RADIATION STRESS
External beam radiation may induce the “Go” phenotype in
tumor cells similarly to the situation described for stress arising
from an adverse tumor microenvironment (Figure 1). Ionizing
radiation at doses used in single fractions during fractionated
radiotherapy has been demonstrated in vitro and by a mouse
study (Wild-Bode et al., 2001) to induce migration, invasion and
spreading of head and neck squamous carcinoma (Pickhard et al.,
2011), lung adenocarinoma (Jung et al., 2007; Zhou et al., 2011),
meningioma (Kargiotis et al., 2008), medulloblastoma (Asuthkar
et al., 2011), and glioblastoma cells (Wild-Bode et al., 2001; Wick
et al., 2002; Badiga et al., 2011; Canazza et al., 2011; Rieken et al.,
2011; Steinle et al., 2011; Kil et al., 2012; Vanan et al., 2012).
The phenomenon of radiation-stimulated migration might be
“grow”
“go”
ionizing radiation
repopulation
FIGURE 1 | Cellular stress such as ionizing radiation induces the
switch from “Grow” to “Go” phenotype.
particularly relevant for highly migrating and brain-infiltrating
glioblastoma cells.
After macroscopic complete resection glioblastoma is usually
treated by adjuvant radiotherapy of the tumor bed applying 54–60
Gy in daily fractions of 1.8–2 Gy combined with temozolomide
(Stupp et al., 2005). The median progression-free survival after
therapy ranges between 5 and 7 months (Stupp et al., 2005).
The recurrence of glioblastoma is typically observed within the
former target volume of the adjuvant fractionated radiotherapy.
This might be due either to a high intrinsic radioresistance of the
glioblastoma cells or to re-invasion of tumor cells into the area
of the irradiated primary. One might speculate that this necrotic
area, meanwhile cleared by phagocytes, offers optimal growth
conditions for such re-invading tumor cells. In this latter scenario,
re-invading cells might be recruited from glioblastoma (stem)
cells pre-spreaded prior to radiotherapy onset in areas outside
the target volume, or from cells that successfully evaded during
radiation therapy.
Radiation-induced up-regulation of integrin- (Wild-Bode
et al., 2001; Nalla et al., 2010; Canazza et al., 2011; Rieken et al.,
2011), VEGF- (Sofia Vala et al., 2010; Badiga et al., 2011; Kil et al.,
2012), EGF- (Kargiotis et al., 2008; Pickhard et al., 2011) or/and
TGFbeta signaling (Canazza et al., 2011; Zhou et al., 2011) has
been proposed to promote tumor cell migration. Downstream
ion transport processes have been reported for glioblastoma cells
(Steinle et al., 2011). In this study, BK K+ channel activation and
subsequent BK-dependent activation of the CaMKII kinase were
identified as key triggers of radiation-induced migration (Steinle
et al., 2011). Additionally, ClC-3 anion channels were identi-
fied as downstream targets of radiation-induced CaMKII activity
(Huber, 2013). This suggests on the one hand motor function
(i.e., volume decrease) of radiation-induced BK and ClC-3 cur-
rents, on the other hand, it points to a signaling function of BK
channels in the programming of radiation-stimulated glioblas-
toma migration (Figure 2). Similar to the situation in migrating
glioblastoma cells, radiation-induced plasma membrane K+ cur-
rents and downstream CaMKII activation have been defined as
key signaling events in cell cycle control of irradiated leukemia
cells as introduced in the following paragraphs.
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2Cl-
K+
Cl- H2O
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glioblastoma cell
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ClC-3
time
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CaMKII
ionizing radiation
[Cl-]
FIGURE 2 | Ionizing radiation (IR)-induced activation of BK K+ channels
results in evasion of glioblastoma cells from radiation stress. Activation
of BK channels occurs upstream of CaMKII and ClC-3 Cl− channels. The
Na+/K+/2Cl− cotransporter accumulates Cl− above its electrochemical
equilibrium. Cl− is used as osmolyte for volume decrease.
DNA REPAIR
Survival of irradiated tumor cells critically depends on DNA
repair. This involves cell cycle arrest, elevated energy consump-
tion, chromatin relaxation, and formation of repair complexes
at the site of DNA damage. Recent in vitro observations suggest
that radiation-induced ion transports may contribute to these
processes in an indirect manner.
Cell cycle control
Survival of irradiated human leukemia cells depends on Ca2+
signaling. Radiation reportedly stimulates Ca2+ entry through
TRPV5/6-like channels and subsequently activates CaMKII,
which in turn fosters G1/S transition, S progression and accumu-
lation in G2 phase of the cell cycle (Heise et al., 2010). Moreover,
Ca2+ signaling in human leukemia cells has been demonstrated
to be tightly regulated by voltage-gated Kv3.4 K+ channels
and translates into G2/M cell cycle arrest by CaMKII-mediated
inhibitory phosphorylation of the phosphatase cdc25B resulting
in inactivation of the mitosis promoting factor and G2/M arrest.
Radiation activates Kv3.4 currents without changing the surface
expression of the channel protein. Most importantly, inhibition of
Kv3.4 by tetraethylammonium and blood-depressing substance-
1 and substance-2 or silencing of the Kv3.4 channels by RNA
interference prevents TRPV5/6-mediated Ca2+ entry, CaMKII
activation, as well as cdc25B inactivation which results in release
from radiation-induced G2/M arrest, increased apoptosis, and
decreased clonogenic survival. Thus, targeting of Kv3.4 radiosen-
sitizes the leukemia cells demonstrating the pivotal role of this
channel in cell cycle arrest required for DNA repair (Palme et al.,
2013). Similar results have been obtained in prostate cancer cells,
where TRPV6 inhibition by capsaicin resulted in radiosensitiza-
tion (Klotz et al., 2011).
Glucose fueling and chromatin relaxation
In addition to cell cycle control, radiation-induced ion trans-
ports are proposed to improve glucose fueling of irradiated tumor
cells. Fast proliferating tumor cells have a high metabolism at
low external glucose and oxygen concentration in the usually
chronically under-perfused growing tumor tissue. At the same
time, many tumor cells cover their high energy requirements
by anaerobic glycolysis with low ATP yield per metabolized
glucose even under normoxic conditions. To sustain sufficient
glucose fueling, tumor cells may up-regulate the Na+/glucose co-
transporter (SGLT). SGLTs are capable to take up glucose into
the tumor cell even against a high chemical gradient (Ganapathy
et al., 2009). Several tumor entities such as colorectal, pancre-
atic, lung, head and neck, prostate, kidney, cervical, mammary,
and bladder cancer as well as chondrosarcomas and leukemia
have indeed been shown to up-regulate SGLTs (Nelson and
Falk, 1993; Ishikawa et al., 2001; Helmke et al., 2004; Casneuf
et al., 2008; Weihua et al., 2008; Yu et al., 2008; Leiprecht
et al., 2011; Wright et al., 2011). The inwardly directed Na+
gradient and the voltage across the plasma membrane drive
the electrogenic SGLT-generated glucose transport into the cell.
The membrane voltage is tightly regulated by the activity of
voltage gated K+ channels which counteract SGLT-mediated
depolarization.
Ionizing radiation has been demonstrated to activate EGF
receptors (Dittmann et al., 2009). In addition, SGLT1 report-
edly is in complex with and under the direct control of
the EGF receptor (Weihua et al., 2008) suggesting radiation-
induced SGLT1 modifications. As a matter of fact, ionizing
radiation stimulates a long lasting EGFR-dependent and SGLT-
mediated glucose uptake in A549 lung adenocarcinoma and
head and neck squamous carcinoma cell lines (but not in
non-transformed fibroblasts) as shown by 3H-glucose uptake
and patch-clamp, current clamp recordings (Huber et al.,
2012). In the latter experiments, radiation-induced and SGLT-
mediated depolarization of membrane potential was preceded
by a transient hyperpolarization of the plasma membrane
indicative of radiation-induced K+ channel activation (Huber
et al., 2012). Such radiation-induced increase in K+ chan-
nel activity has been reported for several tumor cell lines
including A549 lung adenocarcinoma cells (Kuo et al., 1993).
In this cell line, radiation at doses between 0.1 and 6 Gy
stimulates the activity of voltage gated K+ channels within
5min, which gradually declines thereafter. It is tempting to
speculate that this radiation-stimulated K+ channel activ-
ity counteracts the depolarization of the membrane poten-
tial caused by the SGLT activity shortly after radiation and
sustains the driving force for Na+-coupled glucose uptake
(Huber et al., 2012).
Ionizing radiation may lead to necrotic as well as apop-
totic cell death depending on cell type, dose, and fractiona-
tion (Verheij, 2008). In particular, necrotic cell death may be
associated with ATP depletion (Dorn, 2013). Increased SGLT
activity in irradiated tumor cells might contribute to ATP replen-
ishment counteracting necrotic cell death. Such function has
been suggested in irradiated A549 cells by experiments analyz-
ing cellular ATP concentrations, chromatin remodeling, residual
DNA damage, and clonogenic survival of irradiated tumor cells
(Dittmann et al., 2013). The data demonstrate that radiation
of A549 lung adenocarcinoma cells leads to a transient intra-
cellular ATP depletion and to histone H3 modifications crucial
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for both chromatin remodeling and DNA repair in response to
irradiation.
Importantly, recovery from radiation-induced ATP cri-
sis was EGFR/SGLT-dependent and associated with improved
DNA-repair and increased clonogenic cell survival. The block-
ade of either EGFR or SGLT inhibited ATP level recovery and
histone H3 modifications. Vice versa, inhibition of the acetyl-
transferase TIP60, which is essential for histone H3 modification,
prevented chromatin remodeling as well as ATP crisis (Dittmann
et al., 2013). Together, these data suggest that radiation-associated
interactions between SGLT1 and EGFR result in increased glucose
uptake, which counteracts the ATP crisis in tumor cells caused
by chromatin remodeling. Importantly, the blockade of recovery
from ATP crisis by SGLT1 inhibition may radio-sensitize tumor
cells as demonstrated in lung adenocarcinoma and head and neck
squamous carcinoma cell lines (Huber et al., 2012; Dittmann
et al., 2013).
Formation of repair complexes
In addition to SGLT-generated glucose uptake, radiation-induced
electrosignaling via transient receptor potential melastatin 2
(TRPM2) and vanilloid 1 (TRPV1) cation channels, has been
shown to stimulate Ataxia telangiectasia mutated (ATM) kinase
activation, histone 2AX (H2AX) phosphorylation, and γH2AX
focus formation in A549 lung adenocarcinoma cells, processes
required to recruit further repair proteins to the DNA double
strand break (Masumoto et al., 2013). Furthermore, radiation-
induced TRPM2 induces ATP release and P2Y signaling in A549
cells (Masumoto et al., 2013). Radiation-stimulated and P2X7
receptor- and gap junction hemichannel connexin43-mediated
ATP release has been suggested to signal in a paracrine man-
ner to unirradiated bystander cells in the B16 melanoma model
(Ohshima et al., 2012).
Combined, these recent data indicate that ion transports may
regulate processes that mediate intrinsic radioresistance. The
investigation of ion transports in radiobiology is at its very begin-
ning and the few data available are mostly phenomenological in
nature. The molecular mechanisms that underlie, e.g., regula-
tion of DNA repair by ion transports are ill-defined. Nevertheless,
the data prove functional significance of ion transports and
electrosignaling for the survival of irradiated tumor cells
and might have translational implications for radiotherapy in
the future.
Similar to intrinsic radioresistance, the function of ion
transports in hypoxia resistance and associated hypoxic radiore-
sistance of tumor cells is not well-defined. The following para-
graphs give a summary of what is known about mitochondrial
transports and hypoxia resistance of normal tissue and how these
findings might also apply for tumor cells.
MITOCHONDRIAL UNCOUPLING AND RESISTANCE TO HYPOXIA,
CHEMO-, AND RADIOTHERAPY
Intermittent hypoxia is a common feature of vascularized solid
tumors. The pathophysiologial aspects of hypoxia and reoxy-
genation are well-known from ischemia-reperfusion injuries
observed in normal tissue. Reoxygenation-associated produc-
tion of reactive oxygen species (ROS) is a major cause of
the hypoxia/reoxygenation injury after myocardial, hepatic,
intestinal, cerebral, renal and other ischemia and mitochondria
have been identified as one of the main sources of ROS forma-
tion herein (Li and Jackson, 2002). Mitochondrial ROS formation
mutually interacts with hypoxia/reoxygenation-associated cellu-
lar Ca2+ overload. Brief hypoxic periods induce an adaptation
to hypoxia in several tissues which lowers ischemia-reperfusion
injuries of subsequent ischemic insults (so-called ischemic pre-
conditioning). Similar adaptations which involve alterations in
mitochondrial ion transport have been proposed to confer
hypoxia resistance of tumor cells.
Mitochondrial ROS formation
Activity and efficacy of the mitochondrial respiration chain
are fine-tuned by the dependence of the ATP synthase (com-
plex V) on the membrane potential m, by the ATP/ADP
ratio, as well as by reversible phosphorylation of the com-
plexes I and IV (Figure 3) (Kadenbach, 2003). It is suggested
that under physiological conditions (high ATP/ADP ratios),
the membrane potential m is kept low [around −100
to −150mV (Kadenbach, 2003)]. The efficacy of the respira-
tory chain at low m is high. At higher ATP demand or
decreasing cellular ATP levels, cytochrome c oxidase (complex
IV) is relieved from ATP blockade and m increases. High
m values (up to −180mV), however, lower the efficacy
of cytochrome c oxidase (Kadenbach, 2003) and increase the
probability of single electron leakage at complex I and III to
molecular oxygen resulting in an increased O2·− production
(Figure 3) (Korshunov et al., 1997; Skulachev, 1998; Kadenbach,
2003).
The respiratory chain is also regulated by the cytosolic
([Ca2+]i) and mitochondrial matrix free Ca2+ concentration
([Ca2+]m) in a complexmanner (for review see Pizzo et al., 2012).
The phosphatases that dephosphorylate (and thereby switch-off)
the NADH oxidase and that relieve the ATP blockade of complex
IV are inhibited by [Ca2+]m and activated by [Ca2+]i, respectively
(Figure 3). As a consequence, increase in [Ca2+]m and [Ca2+]i
results in a higher m and a concurrently increased production
of reactive oxygen species (Kadenbach, 2003).
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FIGURE 3 | Mitochondrial ROS formation in dependence on m (I, II,
III, and IV, electron transport complexes I, II, III, and IV; Q: semiquinone
radical; cyt C: cytochrome C). Ca2+ and the ATP/ADP ratio regulate the
electron chain at complexes I and IV.
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Hypoxia decreases the activity of the mitochondrial man-
ganese superoxide dismutase (Mn-SOD) and of the cytochrome
c oxidase. Depletion of the final electron acceptor, however,
increases the formation of O2·− during reoxygenation by the
enhanced leakage of single electrons from more proximal com-
plexes of the respiration chain (for review see Li and Jackson,
2002; Sack, 2006). Lowered O2·−-detoxifying capability com-
bined with simultaneous elevated O2·− production results in a
highly elevated O2·− concentration which, e.g., in hepatocytes
increases 15-fold within 15min of reoxygenation (Caraceni et al.,
1995).
Hypoxia/reoxygenation-associated Ca2+ overload
Hypoxia-associated energy depletion and the concomitant
impairment of plasma membrane Na+ and Ca2+ pump activity
lead to a decline of the chemical Na+, Ca2+ and K+ gradi-
ents across the plasma membrane and to the depolarization
of the plasma membrane potential. In parallel, increased lactic
acid fermentation during hypoxia increases the cytosolic proton
concentration and lowers the intracellular pH. The proton extru-
sion machinery that is already active during hypoxia becomes
massively activated during reoxygenation and restores a phys-
iological pH by wash-out of lactic acid and activation of the
sodium/hydrogen exchanger and sodium/bicarbonate symporter.
The latter, Na+-coupled transports, in turn, further increase the
cytosolic Na+ concentration to a level, where the low affinity
high capacity sodium/calcium exchanger in the plasma mem-
brane starts to operate in the reverse mode (i.e., to extrude Na+
at the expense of Ca2+ uptake). At that time, reoxygenation-
mediated oxidative stress (see above) stimulates further Ca2+
entry through Ca2+-permeable channels in the plasma mem-
brane and the release of Ca2+ from the endoplasmic reticulum
resulting in an abrupt rise in [Ca2+]i during the first minutes of
reoxygenation. Cytosolic Ca2+ is buffered by m-driven and
uniporter-mediated Ca2+ uptake into the mitochondrial matrix
which increases [Ca2+]m. Elevated [Ca2+]m and [Ca2+]i val-
ues, in turn, signal back to the respiratory chain by further
increasing m (see above). Exceeding the Ca2+ threshold con-
centration in the matrix, [Ca2+]m activates the permeability
transition pore which leads to breakdown of m, swelling of
the mitochondrial matrix and eventually release of cytochrome
c from the intermembrane space into the cytosol (Crompton,
1999; Rasola and Bernardi, 2011). By reversing the ATP syn-
thase activity, into the ATPase proton pump mode, the F0/F1
complex in the inner mitochondrial delays the break-down of
m at the expense of ATP hydrolysis. In addition to this
ATP depletion, the loss of cytochrome c and the concurrent
decline of the final electron acceptor (cytochrome c oxidase
of complex IV) further increases the formation of O2·− by
more proximal complexes. The pivotal role of membrane trans-
ports in this process is illustrated by the fact that inhibition
of the sodium/hydrogen antiporter in the plasma membrane,
the Ca2+ uniporter in the inner mitochondrial membrane, or
Ca2+ channels in the endoplasmic reticulum (ER) decreases the
hypoxia/reoxygenation injury in vitro (for review see Crompton,
1999; Li and Jackson, 2002; Sack, 2006; Yellon and Hausenloy,
2007).
Ischemic pre-conditioning
Cells can also adapt to repetitive periods of hypoxia. This
so-called ischemic preconditioning has been demonstrated in
the myocardium where it reduces ischemia-caused infarct size,
myocardial stunning, and incidence of cardiac arrhythmias
(Gross and Peart, 2003). Since mitochondrial ROS forma-
tion increases with increasing m (Korshunov et al., 1997;
Skulachev, 1998; Kadenbach, 2003) lowering of the mitochon-
drial m is proposed to be a key adaptation event in ischemic
preconditioning (Sack, 2006). Lowering of m reduces not
only mitochondrial O2·− production but also the mitochon-
drial Ca2+ overload during reoxygenation (Gross and Peart, 2003;
Prasad et al., 2009). The hypoxic preconditioning-associated
reduction of m is in part achieved by up-regulation of ATP-
sensitive (mitoKATP) and Ca2+-activated (mitoKCa) K+ chan-
nels in the inner mitochondrial membrane which short-circuit
m (Murata et al., 2001; Gross and Peart, 2003; Prasad et al.,
2009; Singh et al., 2012; Szabo et al., 2012). The uncoupling
proteins-2 and -3 (UCP-2, -3) constitute two further proteins
that have been suggested to play a role in counteracting cardiac
hypoxia/reoxygenation injury and in hypoxic preconditioning in
heart and brain (Mcleod et al., 2005; Sack, 2006; Ozcan et al.,
2013). Activation of these proteins results in a modest depo-
larization of m by maximally 15mV (Fink et al., 2002).
High expression of UCP-3 has also been demonstrated in skele-
tal muscle where it suppresses mitochondrial oxidant emission
during fatty acid-supported respiration (Anderson et al., 2007).
Accordingly, overexpression of UCP-3 in cultured human muscle
cells lowers m, raises the ATP/ADP ratio, and favors fatty acid
vs. glucose oxidation (Garcia-Martinez et al., 2001). Conversely,
knockdown of UCP-3 increased the coupling between electron
and proton transfer across the inner mitochondrial membrane
and ROS production (Vidal-Puig et al., 2000; Talbot and Brand,
2005). UCP-3 protein is robustly up-regulated in chondrocytes
(Watanabe et al., 2008) and skeletal muscle during hypoxia and
the absence of UCP-3 exacerbates hypoxia-induced ROS (Lu and
Sack, 2008). UCP-3 is not constitutively active. O2·− has been
demonstrated to stimulate the activity of UCP-3 in skeletal mus-
cle suggesting that UCP-3 is the effector of a feed back loop which
restricts overshooting ROS production (Echtay et al., 2002).
Mitochondrial uncoupling in tumor cells
Recent studies suggest that UCPs are upregulated in a number of
aggressive human cancers. In particular, over-expression of UCP2
has been reported in leukemia as well as in breast, colorectal, ovar-
ian, bladder, esophagus, testicular, kidney, pancreatic, lung, and
prostate cancer (Ayyasamy et al., 2011; Su et al., 2012). In human
colon cancer, UCP2 mRNA and protein expression reportedly
is increased by factor of 3–4 as compared to peritumoral nor-
mal epithelium. In addition, UCP2 expression gradually increases
during the colon adenoma-carcinoma sequence (Horimoto et al.,
2004) and is higher in clinical stages III and IV colon cancer than
in stage I and II (Kuai et al., 2010). Similarly, UCP4 expression
has been shown to correlate with lymph node metastases in breast
cancer (Gonidi et al., 2011) and UCP1 expression in prostate can-
cer with disease progression from primary to bone metastatic
cancers (Zhau et al., 2011). Moreover, postmenopausal breast
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tumors with low estrogen receptor (ER) alpha to ER beta ratios
that associate with higher UCP5 expression and higher oxidative
defense have a poor prognosis (Sastre-Serra et al., 2013). Finally,
ectopic expression of UCP2 in MCF7 breast cancer cells has been
demonstrated to enhance proliferation, migration and matrigel
invasion in vitro and to promote tumor growth in vivo (Ayyasamy
et al., 2011). Together, these observations suggest that UCPs may
contribute to the malignant progression of tumor cells.
In addition to malignant progression, UCPsmay alter the ther-
apy sensitivity of tumor cells. In specimens of human ovarian
cancers carboplatin/paclitaxel-resistant cancers showed decreased
UCP2 protein abundances as compared to the sensitive ones
(Pons et al., 2012). Likewise, progression-free and overall survival
of patients with inoperable lung cancer who received cisplatin-
based chemotherapy was higher when tumors expressed high
levels of UCP2 as compared to tumors with low UCP2 levels (Su
et al., 2012). A possible explanation of the latter observation is
that especially in lung tumors with mutated p53, cisplatin elicits
oxidative stress that induces pro-survival signaling. High UCP2
expression, however, diminishes cisplatin-evoked oxidative stress
and, in turn, decreases the pro-survival signals (Su et al., 2012).
In lung cancer cell lines with wildtype p53, in contrast, down-
regulation of UCP2 results in significantly increased paclitaxel-
induced cell death (Su et al., 2012). Similarly, overexpression
of UCP2 in a human colon cancer cell line has been shown to
blunt topoisomerase I inhibitor CPT-11-induced accumulation
of reactive oxygen species and apoptosis in vitro and to con-
fer CPT-11 resistance of tumor xenografts (Derdak et al., 2008).
In addition, in pancreatic adenocarcinoma, non-small cell lung
adenocarcinoma, and bladder carcinoma cell lines IC50 values
of the anticancer drug gemcitabine increase with intrinsic UCP2
mRNA abundance. Furthermore, UCP2 overexpression strongly
decreases gemcitabine-induced mitochondrial superoxide forma-
tion and protects cancer cells from apoptosis (Dalla Pozza et al.,
2012). Finally, metabolic changes including UCP2 up-regulation
and UCP2-mediated uncoupling of oxidative phosphorylation
have been demonstrated in multidrug-resistant subclones of var-
ious tumor cell lines (Harper et al., 2002). Similarly, in acute
myeloid leukemia cells, UCP2 up-regulation has been shown to
foster the Warburg effect (i.e., anaerobic glycolysis in the absence
of respiratory impairment) (Samudio et al., 2008).
UCP2 expression is stimulated by co-culturing of these
leukemia cells with bone marrow-derived mesenchymal stro-
mal cells (Samudio et al., 2008). Other stimuli of UCP expres-
sion/activity are hydrogen peroxide as shown for UCP5 in colon
cancer cells (Santandreu et al., 2009) and gemcitabine chemother-
apy as reported for UCP2 in pancreatic, lung and bladder cancer
cell lines (Dalla Pozza et al., 2012). Collectively, these data sug-
gest that tumor cells may acquire resistance to chemotherapy
by up-regulation of UCPs and lowering of the therapy-evoked
mitochondrial formation of reactive oxygen species (Robbins and
Zhao, 2011).
Accordingly, experimental targeting of UCPs has been demon-
strated to sensitize tumor cells to chemotherapy in vitro. For
instance, genipin-induced inhibition or glutathionylation of
UCP2 sensitizes drug-resistant leukemia subclones to chemother-
apy with menadione, doxorubicin, or epirubicin (Mailloux
et al., 2010; Pfefferle et al., 2012). Likewise, UCP2 inhibi-
tion by genipin or UCP2 mRNA silencing strongly enhances
gemcitabine-induced mitochondrial superoxide generation and
apoptotic cell death of pancreatic, lung and bladder cancer cell
lines (Dalla Pozza et al., 2012). Moreover, UCP2 inhibition
has been reported to trigger reactive oxygen species-dependent
nuclear translocation of GAPDH and autophagic cell death in
pancreatic adenocarcinoma cells (Dando et al., 2013) Together,
this suggests that targeting UCPsmight be a promising strategy to
overcome resistance to anti-cancer therapies in the clinic. Notably,
in an acute myeloid leukemia cell line, the cytotoxicity of cisplatin
has been proposed to be in part mediated by cisplatin-dependent
down-regulation of UCPs (Samudio et al., 2008) suggesting that
established chemotherapy regimes already may co-target UCPs.
It is tempting to speculate that UCPs may also confer resis-
tance to radiotherapy. One could hypothesize that UCPs adapt
the tumor cells to a “relatively radioprotected” hypoxic microen-
vironment by decreasing hypoxia-associated mitochondrial for-
mation of reactive oxygen species. Such UCP function in hypoxia
resistance has been demonstrated for a lung adenocarcinoma
cell line (Deng et al., 2012). Notably, radiation induces up-
regulation of UCP2 expression as shown in colon carcinoma cells
(Sreekumar et al., 2001) and in a radiosensitive subclone of B cell
lymphoma (Voehringer et al., 2000). On the one hand, this UCP2
up-regulationmight facilitate radiation-induced apoptosis induc-
tion by accelerating the break-down of m as proposed by the
authors of these studies. On the other hand, radiation-induced
UCP2 upregulation might be radioprotective by lowering the
radiation-induced burden of reactive oxygen species. As a matter
of fact, multi-resistant subclones of leukemia cells show higher
UCP2 protein expression, lower m, lower radiation induced
formation of reactive oxygen species and decreased DNA damage
as compared to their parental sensitive cells (Harper et al., 2002).
In summary, UCPs suppress the formation of O2·−, a byprod-
uct of the mitochondrial respiration chain and a major source
of oxidative stress. In some cancers UCPs in particular UCP2
are highly upregulated and may contribute to the reprogram-
ming of the cell metabolism that results in chemoresistance (for
review see Baffy, 2010; Baffy et al., 2011) or even radioresis-
tance. Moreover, recent studies imply that UCP2 may repress
p53-mediated apoptosis providing a potential new mechanism
of how UCP2 contributes to cancer development (Robbins and
Zhao, 2011).
Together, these observations suggest that ion transport pro-
cesses are critically involved in evasion from radiation stress,
and intrinsic or hypoxic radioresistance. Since ion transport-
mediated radioresistance might underlie failure of radiotherapy,
concepts which combine ion transport targeting with radiother-
apy hold promise for new therapy strategies in the future. A
summary of how ion transport can be harnessed for anticancer
therapy and how these therapy strategies might be combined with
radiotherapy is given in the next paragraphs.
TARGETING ION TRANSPORTS IN RADIOTHERAPY
An important reason for the study of ion transports in the context
of radiotherapy is the possible translation of the acquired knowl-
edge into anti-cancer therapy. Many pharmacological modulators
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of ion transports are already in clinical use or currently tested in
clinical trials (Wulff and Castle, 2010). Moreover, tumors often
over-express certain types of transport proteins.
These proteins such as the transient receptor melastatin 8
(TRPM8) non-selective cation channel in prostate cancer have
been used in clinical trials as tumor-associated antigen for
anti-tumor vaccination (Fuessel et al., 2006). Tumor promot-
ing inflammation and anti-tumor immune effects are evolving
fields of preclinical and clinical research (Hanahan andWeinberg,
2011). Preclinical evidence supports the thesis that tumors have
to develop immune-evading capacities in order to grow into
macroscopic, clinically detectable lesions (Koebel et al., 2007;
Teng et al., 2008). Possible mechanisms are the secretion of
cytokines and chemokines by cancer and tumor stroma cells
(Vianello et al., 2006; Shields et al., 2010), the priming of infiltrat-
ing T-lymphocytes toward immunosuppressive regulatory T-cells
and the recruitment of myeloid-derived suppressor cells and
tumor-associated macrophages (Tanchot et al., 2013; Oleinika
et al., 2013). Irradiation of tumors has been shown to impair
on the one hand the immunosuppressive action of the tumor
and on the other to induce so-called “immunogenic” cell death
within the tumor with translocation of calreticulin to the plasma
membrane, release of HMGB1 or ATP (Formenti and Demaria,
2013). Preclinical studies showed a synergistic effect of irradia-
tion and several immunotherapeutic approaches such as dendritic
cell injection (Finkelstein et al., 2012), anti-CTLA-4-antibody
(Grosso and Jure-Kunkel, 2013), and vaccines (Chakraborty et al.,
2004). Interestingly, for combination with anti-CTLA-4 antibody
a synergistic effect could only be demonstrated for fraction-
ated but not for single-dose irradiation (Demaria and Formenti,
2012).
In addition, over-expressed transport proteins in tumors can
be harnessed to target drugs, cytokines, or radioactivity to the
tumor cells (Hartung et al., 2011). One example is the specific
surface expression of ClC-3 Cl− channels by glioblastoma (and
other tumor entities) which suggests ClC-3 as an excellent and
highly specific target for anti-glioblastoma therapy. Chlorotoxin
which is a 36 amino acid-long peptide from the venom of the
scorpion Leiurus quinquestriatus has been found to inhibit ClC-
3 and to preferentially bind to the cell surface of a variety of
human malignancies. This specificity probably comes from the
highly affine binding of chlorotoxin to a lipid raft-anchored
complex of matrix metalloproteinase-2, membrane type-I MMP,
and transmembrane inhibitor of metalloproteinase-2, as well as
ClC-3 (Veiseh et al., 2007). Ongoing clinical trials successfully
used 131I-labeled chlorotoxin as glioblastoma-specific PET-tracer
(Hockaday et al., 2005) and for targeted radiation of glioblas-
toma cells (Mamelak and Jacoby, 2007). Due to the low surface
expression of ClC-3 in normal tissue, chlorotoxin exhibits little
or no affinity to normal cells (Lyons et al., 2002). If the in vitro
and mouse data on radiation-stimulated glioblastoma migration
reflect indeed the in vivo situation in glioblastoma patients, a
clinical setting might be envisaged in which radiation-induced
glioblastoma spreading is prevented by combining radiotherapy
with chlorotoxin blockade of ClC-3 channels.
CONCLUDING REMARKS
Interdisciplinary approaches linking radiobiology with physiol-
ogy brought about the first peaces of evidence suggesting a
functional significance of ion transport processes for the sur-
vival of irradiated tumor cells. The few reports published up
to now on this topic are confined to phenomena occurring in
the plasma membrane due to the methodological restrictions
of studying these processes in the membranes of mitochondria,
endoplasmic reticulum, or nuclear envelope. Intracellular mem-
brane transports, however, might similarly impact tumor cell
radiosensitivity. This is suggested by the notion that intracellular
Cl− channel CLIC1 protein expression regulates radiosensitivity
in laryngeal cancer cells (Kim et al., 2010). However, the molec-
ular mechanisms underlying, e.g., radiation-induced transport
modifications, or downstream signaling events are far from being
understood. Despite all these limitations, our current knowledge
already clearly indicates that the observed transport processes
may be crucial for the survival of the tumor and, thus, are worth-
while to spend further and more effort in this field which might
lead to new strategies for cancer treatment in the future.
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